Skip to main content
Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: RETRACTED ARTICLE: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis

Fig. 7

Distribution of integrin α5β1, αvβ3 and VEGFR2 on EAhy926 cell surface after HM-3 and Sunitinib treatment. a Treatment strategy. Samples 1–6 are membrane fractions outside of the lipid raft region and samples 7–12 are membrane fractions inside the lipid raft region of the corresponding cells. b Detection of human transferrin R (non-raft marker) and caveolin-1 (raft marker) with Western-blot analysis. Glypican-1 was also analysed. c Western-blot analysis showing redistribution of integrin α5β1 and αvβ3 after HM-3 and Sunitinib treatment. Intensities of the protein bands were analyzed with Image J and shown as histograms in panel d for integrin α5β1 and panel e for integrin αvβ3. Statistical analysis was performed with VEGF induced samples (sample 2 and 8) for comparison of non-raft and raft fractions. f Western-blot analysis showing redistribution of VEGFR2 and p-VEGFR2 after HM-3 and Sunitinib treatment. Intensities of the protein bands were shown as histograms in panel g for VEGFR2 and panel h for p-VEGFR2. Statistical analysis was performed comparing sample 2 or 8. i Immunoprecipitation was performed with anti-integrin αvβ3 antibodies and VEGFR2 or p-VEGFR2 was detected with Western-blot analysis to show distribution of integrin αvβ3-VEGFR2 complexes and the corresponding p-VEGFR2. Intensities of the protein bands were analyzed with Image J and shown as histograms in panel j for VEGFR2 and panel k for p-VEGFR2. Statistical analysis was performed comparing sample 2 for the non-raft region and sample 8 for the raft region. Data are represented as mean ± SD (*p<0.05, **p<0.01)

Back to article page